Drugs / EXARAFENIB
EXARAFENIB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04913285 | Aug 2021 → Nov 2028 expected | melanoma, non-small cell lung carcinoma | Pierre Fabre Laboratories | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXARAFENIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095099 ↗ |
| Known as | EXARAFENIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095099 ↗ |
| Known as | KIN-2787 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04913285 ↗ |
| Known as | KIN-2787 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095099 ↗ |
| Action | Inhibit | “KIN-2787, a RAF small molecule kinase inhibitor” NCT04913285 ↗ |
| Modality | Small molecule | “KIN-2787, a RAF small molecule kinase inhibitor” NCT04913285 ↗ |
| Route | Oral | “KIN-2787 will be administered orally twice daily in 28-day cycles” NCT04913285 ↗ |